Go to the list of all blogs
published in Blogs
Aug 10, 2026
Albemarle (ALB): Evaluating the Path to $200 After a -35% Pullback

Albemarle (ALB): Evaluating the Path to $200 After a -35% Pullback

Key Takeaways

  • Albemarle Corporation (NYSE: ALB) currently trades near $131, having pulled back more than 35% from its 52-week high of $221, placing the $200 target roughly 52% above current levels.
  • A recovery in lithium prices to approximately $20,000 per metric ton, combined with accelerating energy storage demand and improving electric vehicle (EV) sales, represents the strongest case for ALB reaching $200.
  • Multiple prominent analysts maintain price targets at or above $200, including Morningstar's $200 fair value estimate, Wells Fargo's $200 target, and Truist Financial's $225 target.
  • The biggest obstacles include persistent lithium oversupply concerns, potential demand weakness in China, and Albemarle's negative trailing earnings profile that keeps valuation debates alive.
  • Investors should monitor lithium spot prices, quarterly Energy Storage segment margins, and global EV adoption rates as the key catalysts that could determine whether $200 becomes reality.

Why the $200 Level Matters

Albemarle Corporation, the world's largest lithium producer and a key player in the global EV battery supply chain, has seen sharp swings over the past year. After climbing from under $70 to a 52-week high of $221, the stock has given back a sizable portion of those gains and now sits near $131 as of early August 2026. The $200 price target draws attention because it aligns with several analyst estimates, serves as a notable round number, and would indicate that the market sees lasting strength in the lithium recovery and Albemarle's improving earnings power.

Albemarle's Business Snapshot

Albemarle develops and manufactures specialty chemicals, with its Energy Storage segment—the source of lithium carbonate, lithium hydroxide, and other battery-grade compounds—driving most earnings. A Specialties segment focuses on bromine and related lithium solutions. Headquartered in Charlotte, North Carolina, the company operates more than 25 production and research sites worldwide and holds over 1,500 active patents. With a market capitalization of roughly $15.5 billion and trailing twelve-month revenue of $5.91 billion, ALB stands as the leading publicly traded pure-play lithium name.

Recent Financial Performance

Albemarle's results have strengthened in recent quarters. First-quarter 2026 net sales reached $1.4 billion, up 33% year-over-year, supported by higher lithium prices and improved volumes. Adjusted EBITDA rose to $664 million in Q1, reflecting about 148% growth from the prior-year period. The company produced $346 million in operating cash flow and $248 million in free cash flow, while repaying $1.3 billion in debt and lowering its weighted average interest rate to around 3.1%. A forward P/E near 14 and price-to-book value of about 1.9 show that valuation has eased from earlier 2026 peaks, which could make the $200 target more attainable if earnings momentum holds. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Potential Drivers for Further Gains

The core case for ALB reaching $200 centers on sustained lithium price strength. Lithium spot prices have averaged around $20,000 per metric ton in 2026, close to Morningstar's long-term marginal cost of production estimate. Management guided for continued solid volumes, with 53,000 metric tons of lithium carbonate equivalent sold in Q1 at an average realized price of roughly $17 per kilogram. Broader demand trends support the outlook as global EV sales keep rising and utility-scale battery energy storage systems add a new growth avenue. Analysts at Truist Financial and BMO Capital have pointed to energy storage shipment growth when maintaining targets above $200. Albemarle's cost-cutting efforts, aimed at $100 million to $150 million in annual savings, along with 2026 capital spending guidance of $550 million to $600 million, should aid margin expansion and cash flow. From what I see, these elements could provide meaningful support if they unfold as expected.

Risks That Could Limit Upside

Even with better fundamentals, several factors might keep $200 out of reach. Some forecasts still point to structural oversupply in lithium markets, and restarts at CATL's lithium mine have sparked worries about renewed price pressure. Albemarle's trailing net income stays negative, though the company has returned to quarterly profitability. Geopolitical issues add uncertainty—the firm estimated $70 million to $90 million in unmitigated supply-chain cost impacts from Middle East disruptions. After a gain of more than 89% over the past year, much of the recovery story may already be reflected in the price. Insider selling, including share sales by CEO Kent Masters earlier in 2026, warrants attention as well.

Analyst Price Targets

S&P Global data shows 22 analysts covering Albemarle with a consensus "Buy" rating and an average 12-month price target of about $174. The range spans widely from $83 on the low end to $225 on the high end, highlighting differing views on lithium's direction. Bullish calls include Truist Financial at $225, BMO Capital and Wells Fargo at $200, and Morningstar's $200 fair value estimate, which sees shares as undervalued. More cautious views come from Mizuho Securities at $160 (Hold) and Evercore ISI at $180. This spread suggests the route to $200 is possible but not assured.

Important Technical Levels

Technically, ALB encounters several key zones on the way to $200. The recent bounce from the $117-$125 area points to emerging support, yet the stock must first reclaim the $150-$160 region, which shifted from support in June 2026 to resistance. The $180 level marks another hurdle, near Evercore ISI's target and the 200-day moving average zone. A sustained break above $180 would likely bring $200 into focus quickly given its psychological and analyst importance. The 52-week high of $221 remains the next major resistance beyond that level. I also ran a quick review using Tickeron’s AI Trend Prediction Engine to assess momentum signals around these areas.

Enhancing Research with AI Tools

As part of my ongoing analysis of volatile names like Albemarle, I find Tickeron's AI Daily Buy/Sell Signals particularly useful. These tools apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical patterns and market shifts. They help identify opportunities and monitor positions in a systematic way that complements traditional fundamental work when evaluating whether ALB can advance toward the $200 level.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: ALB

ALB's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ALB turned positive on July 22, 2026. Looking at past instances where ALB's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on ALB as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

ALB moved above its 50-day moving average on August 19, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ALB crossed bullishly above the 50-day moving average on August 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALB advanced for three days, in of 312 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for ALB moved below the 200-day moving average on July 24, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ALB broke above its upper Bollinger Band on August 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ALB entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (7.001). ALB's P/E Ratio (530.556) is considerably higher than the industry average of (39.393). Projected Growth (PEG Ratio) (0.959) is also within normal values, averaging (2.393). Dividend Yield (0.011) settles around the average of (0.019) among similar stocks. P/S Ratio (3.078) is also within normal values, averaging (70.976).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.

Notable companies

The most notable companies in this group are DuPont de Nemours (NYSE:DD), Chemours Company (The) (NYSE:CC).

Industry description

The specialty chemicals sector includes companies that produce chemicals and industrial gases, which are of relatively high-value, often made to customer specifications. Examples of specialty chemicals are electronic chemicals, industrial gases, coatings, adhesives and sealants, industrial and institutional cleaning chemicals. The products are often valued on the basis of their purposes/performances rather than for their composition. Linde Plc, Ecolab Inc., Air Products and Chemicals, Inc., and Dow, Inc. are some of the largest companies making specialty chemicals.

Market Cap

The average market capitalization across the Chemicals: Specialty Industry is 12.06B. The market cap for tickers in the group ranges from 47 to 224.76B. LIN holds the highest valuation in this group at 224.76B. The lowest valued company is GTBT at 47.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Specialty Industry was -1%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 6%. CITR experienced the highest price growth at 21%, while LWLG experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Specialty Industry was 25%. For the same stocks of the Industry, the average monthly volume growth was -14% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 58
Price Growth Rating: 51
SMR Rating: 77
Profit Risk Rating: 81
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
ALB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of specialty polymers, chemicals and related products

Industry ChemicalsSpecialty

Profile
Details
Industry
Chemicals Specialty
Address
4250 Congress Street
Phone
+1 980 299-5700
Employees
9000
Web
https://www.albemarle.com
Interact to see
Advertisement
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
EDSA (Edesa Biotech) is up more than 21% today largely on speculative trading in a very illiquid penny stock with no clear, company‑specific news catalyst, likely driven by technical factors, retail flows, and short‑term trading rather than fundamentals.
Q4 2025 revenue came in strong at about 214–215 million, up mid‑30s percent year over year and a few percent above estimates, but GAAP EPS was only 0.08 versus expectations around 0.31, a roughly 70–75% miss and down from 0.13 a year earlier.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.